Marinus Pharmaceuticals (NASDAQ: MRNS)
Marinus Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Marinus Pharmaceuticals Company Info
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.
News & Analysis
3 Biotech Stocks That Surged Last Week
Find out what's behind their big run-ups to see if they can make it happen again.
Why Marinus Pharmaceuticals Stock Skyrocketed 80% Higher Today
Investors are thrilled with the results from a late-stage clinical study of the company's only pipeline drug candidate.
Nasdaq Rises Despite Nikola Hit; Marinus Soars
The tech-heavy index is bouncing back from recent weakness.
Here's Why Marinus Pharmaceuticals Stock Is Collapsing Today
Wall Street is not sold on the latest clinical results.
Here's Why Marinus Pharmaceuticals Is Sinking Today
A secondary offering on the way isn't what investors wanted to hear.
Here's Why Marinus Pharmaceuticals Inc. Fell as Much as 20.1% Today
The small biopharma announced second-quarter 2018 results and gave a business update.
Here's Why Marinus Pharmaceuticals Rose as Much as 18.4% Today
The tiny biopharma is back on the upswing following an analyst upgrade.
Here's Why Marinus Pharmaceuticals Dropped as Much as 17.7% Today
The biopharma's slide continues -- for good reason this time.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.